Program for the Assessment of Clinical Cancer Tests (PACCT): Implementing promising assays into clinical practice

Expert Review of Molecular Diagnostics

Volumn 5, Issue 3, 2005, Pages 271-273

  Jessup, J Milburn ^b   Lively, Tracy G ^a   Taube, Sheila E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ASSAY; CANCER DIAGNOSIS; CANCER TEST; CLINICAL PRACTICE; EDITORIAL; EVALUATION; LABORATORY TEST; VALIDATION PROCESS;

HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 18844428607     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.5.3.271     Document Type: Editorial

References (3)

1. Thor A, Berry D, Budman D et al. erbB2, p53, and adjuvant therapy interactions in node positive breast cancer. J. Natl Cancer Inst. 90, 1346-1360 (1998).
2. Paik S, Bryant J, Park C et al. erbB2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl Cancer Inst. 90, 1361-1370 (1998).
3. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).